Literature DB >> 6329509

Etoposide infusions for treatment of metastatic lung cancer.

W P Steward, N Thatcher, J M Edmundson, W Shiu, P M Wilkinson.   

Abstract

Etoposide was given by three weekly 24-hour infusions (600 mg/m2) to 35 patients with extensive-stage lung cancer. Only two partial responses were achieved; both were of short duration. Pharmacokinetic data suggested that low peak serum concentrations of etoposide were obtained, and it is suggested that if this method of administration is used, higher doses of etoposide be employed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6329509

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  3 in total

1.  The pharmacokinetics of high dose cyclophosphamide and high dose etoposide.

Authors:  D Cunningham; J Cummings; R B Blackie; L McTaggart; S W Banham; S B Kaye; M Soukop
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

Review 2.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

3.  Paclitaxel and etoposide co-loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma.

Authors:  Bing Wang; Xiu-Chun Yu; Song-Feng Xu; Ming Xu
Journal:  J Nanobiotechnology       Date:  2015-03-21       Impact factor: 10.435

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.